Tatva Chintan Pharma Chem Share Price

NSE
TATVA •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or Open Demat Account for live prices.
Start SIP in Tatva Chintan Pharma Chem Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
46.31% Fall from 52W High
-9
TTM PE Ratio
High in industry
117.7
Price to Book Ratio
Below industry Median
2.8
Dividend yield 1yr %
Below industry Median
0.2
TTM PEG Ratio
PEG TTM is negative
-1.9

Tatva Chintan Pharma Chem Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Tatva Chintan Pharma Chem Ltd Quarterly Revenue

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
83.49 Cr
105.46 Cr
98.27 Cr
84.21 Cr
96.67 Cr

Tatva Chintan Pharma Chem Ltd Yearly Revenue

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
401.01 Cr
429.36 Cr
442.54 Cr
306.29 Cr
264.62 Cr

Tatva Chintan Pharma Chem Ltd Quarterly Net Profit/Loss

Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
-0.66 Cr
5.21 Cr
9.61 Cr
3.46 Cr
7.78 Cr

Tatva Chintan Pharma Chem Ltd Yearly Net Profit/Loss

Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020
30.35 Cr
45.49 Cr
95.87 Cr
52.26 Cr
37.79 Cr

Tatva Chintan Pharma Chem Ltd shareholding Pattern

Promoter
72%
Foreign Institutions
3.3%
Mutual Funds
6.8%
Domestic Institutions
6.9%
Public
17.8%
Promoter
72%
Foreign Institutions
3.4%
Mutual Funds
10.6%
Domestic Institutions
10.6%
Public
14%
Promoter
72%
Foreign Institutions
3.6%
Mutual Funds
12.8%
Domestic Institutions
12.9%
Public
11.5%
Promoter
72%
Foreign Institutions
4.2%
Mutual Funds
13%
Domestic Institutions
13.1%
Public
10.7%
Promoter
72%
Foreign Institutions
4.4%
Mutual Funds
13.5%
Domestic Institutions
13.8%
Public
9.8%
Promoter
79.2%
Foreign Institutions
3.2%
Mutual Funds
10.8%
Domestic Institutions
11.1%
Public
6.6%

Tatva Chintan Pharma Chem Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
4
Bearish Moving Averages
12
5Day EMA
894.90
10Day EMA
889.90
12Day EMA
887.60
20Day EMA
883.50
26Day EMA
884.90
50Day EMA
904.50
100Day EMA
956.30
200Day EMA
1,072.40
5Day SMA
898.40
10Day SMA
891.70
20Day SMA
867.40
30Day SMA
868.70
50Day SMA
905.00
100Day SMA
950.00
150Day SMA
998.40
200Day SMA
1,051.20
Delivery & Volume

Delivery & Volume

PeriodCombined Delivery VolumeNSE+BSE Traded Volume
Day Rs
6298 Rs
14254 Rs
Week Rs
17421 Rs
32401 Rs
Month Rs
11873 Rs
23603 Rs
Resistance & Support
889.82
Pivot
Resistance
First Resistance
899.63
Second Resistance
912.87
Third Resistance
922.68
Support
First Support
876.58
Second support
866.77
Third Support
853.53
Relative Strength Index
50.33
Money Flow Index
73.32
MACD
2.76
MACD Signal
-3.51
Average True Range
28.87
Average Directional Index
17.23
Rate of Change (21)
0.47
Rate of Change (125)
-13.07

Tatva Chintan Pharma Chem Ltd Company background

Founded in: 1996
Managing director: Chintan Nitinkumar Shah
Tatva Chintan Pharma Chem Limited was formerly incorporated as Tatva Chintan Pharma Chem Private Limited on 12 June 1996. The status of the Company converted from Private Limited into a Public Limited Company effective from 27 January 2021 and the name of Company also changed from Tatva Chintan Pharma Chem Private Limited to Tatva Chintan Pharma Chem Limited. The Company is promoted by Mr. Chintan Nitin Kumar Shah, Mr. Ajay Kumar Mansukhlal Patel and Mr. Shekhar Rasiklal Somani. The Company is a globally recognized specialty chemical player with several market leading products in its portfolio. The Company is primarily engaged in manufacturing, distribution and selling of specialty chemicals i.e., Phase Transfer Catalysts (PTC), , Structure Directing Agents (SDA), Electrolyte Salts and Solutions (ESS), Pharmaceutical and Agrochemical Intermediates and Other Specialty Chemicals (PASC). These products cater to diverse industries such as pharmaceuticals, agrochemicals, automotive, electronics, resins and polymers, flavours and fragrances, personal care and disinfectants, oil field and energy storage.The Company operate through two world class manufacturing facilities located at Dahej and Ankleshwar in Gujarat both of which are strategically located very close to the Hazira Port. These units provide the Company cost and logistics advantage and enabling seamless export and import operations. The Companys manufacturing facilities obtained ISO 9001:2015 and 14001:2015 certification for robust quality management systems. Employing modern equipment like reactors, assembly lines, ANFDs, centrifuges and RCVDs, enabled the Company to undertake multiple chemistry process. The Company successfully established an integrated model comprising world class manufacturing infrastructure, complex chemical processes, warehousing facilities and technically sound RD capabilities, which enables to achieve high operational efficiency and quality, to innovate customize and to ensure sustainable operations with wide offerings. The Company has sophisticated quality control lab equipped with modern analytical equipment, enabling it to detect impurities upto PPM levels and achieve ultrapuregrade certification. The Company Promoters identified an opportunity in manufacturing Phase Transfer Catalyst (PTC), which is a niche segment within the specialty chemicals space. With PTC as the base, the Company have marked presence in the entire value chain including PTC, Structure Directing Agents (SDA), Electrolyte Salts (ES) and Pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC).The Company have a dedicated Department of Scientific and Industrial Research (DSIR) approved RD centre at its Vadodara facility where qualified and experienced inhouse RD team focus on development of new products and improvement in current manufacturing processes. The Company is having modern systems and analytical development laboratory with stateoftheart instrumentation.In 2004, the Company received licence from the FDA, Gujarat at its Ankleshwar manufacturing plant.In 2007, the Company commenced Ankleshwar manufacturing facility and increased the expansion of manufacturing capacity.In 2011, the Company started commercial manufacturing of Structure Directing Agents (SDA).In 2015, the Company was accredited Appreciation Certificate for the Ankleshwar Plant from the Office of the Chief Commission of Central Excise, Customs Service Tax, Vadodara Zone for its contribution to revenue and voluntary compliance with tax laws. The Company achieved revenue of nearly Rs 1 bn. The Company established a warehousing plant in The Netherlands. Tatva Chintan USA Inc. was incorporated as a wholly owned Subsidiary of TCPCL.In 2016, the Company was accorded the status of a twostar export house for the Ankleshwar plant from the Directorate General of Foreign Trade (DGFT), Ministry of Commerce and Industry (MoCI), Government of India (GoI).In 2017, manufacturing plant was established in Dahej, Gujarat. In 2018, the RD facility was set up in Vadodara.Tatva Chintan Europe BV, was incorporated as wholly owned Subsidiary of the Company in year 2019.In FY 201920, the Companys Ankleshwar unit was converted to a zero liquid effluent discharge facility. The products proved efficiency to ensure lower byproducts and waste generation in chemical processes.Additionally, the Company participated in the Together for Sustainability initiatives whereby sustainability sourcing practices of chemical suppliers, like ecological and social aspects were assessed. Under this initiative, the Company involved Ecovadis to audit sustainability practices and performance, the results of which were above the industry average. This created a robust initiative and focused on retaining key customers who consider sustainability an important parameter to do business. In 2020, the Company achieved another Rs 2 billion revenue.In 2021, the manufacturing capacity at Dahej facility in Gujarat increased giving rise to aggregate installed reactor manufacturing capacity of the Company from 160 KL and 10 Assembly Lines to 280 KL and 17 Assembly Lines respectively.The Company launched its Initial Public Offer cum Offer for Sale of 46,16,804 Equity Shares by raising funds from public aggregating to Rs 500 Crore, comprising a Fresh Issue of 20,77,562 Equity Shares aggregating to Rs 225 Crore and an Offer for Sale of 25,39,242 Equity Shares aggregating to Rs 275 Crore in July, 2021. The Company commenced commercial production from the newly expanded facility at Dahej SEZ. With this, the installed reactor capacity increased to 500 KL from 294 KL and assembly lines increased from 27 to 39 in 202324.
Read More

Tatva Chintan Pharma Chem Ltd FAQs

Tatva Chintan Pharma Chem Ltd shares are currently priced at 886.4 on NSE and 887.55 on BSE as of 12/12/2024 12:00:00 AM. Please be aware that stock prices are subject to continuous fluctuations due to various factors.

The past 1-year return of Tatva Chintan Pharma Chem Ltd [TATVA] share was -44.56. The Tatva Chintan Pharma Chem Ltd [TATVA] share hit a 1-year low of Rs. 788.5 and a 1-year high of Rs. 1650.85.

The market cap of Tatva Chintan Pharma Chem Ltd is Rs. 2073.47 Cr. as of 12/12/2024 12:00:00 AM.

The PE ratios of Tatva Chintan Pharma Chem Ltd is 156.26 as of 12/12/2024 12:00:00 AM.

The PB ratios of Tatva Chintan Pharma Chem Ltd is 2.87 as of 12/12/2024 12:00:00 AM

The Mutual Fund Shareholding was 6.76% at the end of 12/12/2024 12:00:00 AM.

You can easily buy Tatva Chintan Pharma Chem Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -